Full history for every metric is available with a Kvantra account
Tricida, Inc. (TCDA)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -159 | -124 | |||||
| Net profit | $m | -29 | -41 | -103 | -177 | -265 | -194 | -144 |
| EPS reported | $ | -3.88 | -2.56 | |||||
| Operating cashflow per share | $ | -2.80 | -2.80 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -2.80 | -2.80 | |||||
| Free cash flow | $m | -140 | -109 | |||||
| Net debt | $m | 1 | 115 | |||||
| Book value equity | $m | - | - | |||||
| Book value per share | $ | 0.00 | - | |||||
| Number of shares | m | 50.03 | 58.02 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2,193.88 | 24.78 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -3.41 | -0.05 | |||||
| EV/EBITDA LTM | x | -3.64 | -0.98 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -40.60% | -3593.7% | |||||
| FCF Yield | % | -29.30% | -1828.1% | |||||
| Quality | ||||||||
| ROE | % | -89067.9% | -355.98% | |||||
| ROIC | % | -112.13% | -112.13% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.99 | -0.52 | |||||
| Net Debt/EBITDA | x | -0.73 | -0.73 | |||||
| EBIT/Net interest | x | -9.03 | -9.03 | |||||
| Net debt/market cap | % | 0.21% | 1934.2% | |||||
| Net debt/Equity | x | - | - | |||||
| Gross debt/equity | x | - | - | |||||
Company overview
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Tricida, Inc. (TCDA)
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free